Bone Biologics Corp Stock Today
| BBLG Stock | USD 1.31 0.06 4.80% |
Performance3 of 100
| Odds Of DistressOver 79
|
Bone Biologics is trading at 1.31 as of the 25th of November 2024. This is a 4.80% increase since the beginning of the trading day. The stock's lowest day price was 1.14. Bone Biologics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Bone Biologics Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of February 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 31st of March 2016 | Category Healthcare | Classification Health Care |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company was founded in 2004 and is headquartered in Burlington, Massachusetts. Bone Biologics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. The company has 2.46 M outstanding shares of which 72.06 K shares are currently shorted by private and institutional investors with about 0.18 trading days to cover. More on Bone Biologics Corp
Moving against Bone Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Bone Stock Highlights
| CEO President | Jeffrey Frelick | |||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||
Financial Strength
| ||||||||||||||||
Debt LevelsBone Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bone Biologics' financial leverage. It provides some insight into what part of Bone Biologics' total assets is financed by creditors.
| ||||||||||||||||
Bone Biologics Corp (BBLG) is traded on NASDAQ Exchange in USA. It is located in 2 Burlington Woods Drive, Burlington, MA, United States, 01803 and employs 2 people. Bone Biologics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.08 M. Bone Biologics Corp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 2.46 M outstanding shares of which 72.06 K shares are currently shorted by private and institutional investors with about 0.18 trading days to cover.
Bone Biologics Corp currently holds about 5.45 M in cash with (9.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53.
Check Bone Biologics Probability Of Bankruptcy
Ownership AllocationBone Biologics Corp shows 5.21 percent of its outstanding shares held by insiders and 4.58 percent owned by other corporate entities.
Check Bone Ownership Details
Bone Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ubs Group Ag | 2024-06-30 | 33.7 K | |
| Hrt Financial Llc | 2024-06-30 | 17.5 K | |
| Tower Research Capital Llc | 2024-06-30 | 5.8 K | |
| Mcmahon Financial Advisors, Llc | 2024-09-30 | 403 | |
| Bank Of America Corp | 2024-06-30 | 9.0 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Armistice Capital, Llc | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-06-30 | 0.0 |
Bone Biologics Historical Income Statement
Bone Stock Against Markets
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.